Nebivololo Aurobindo Italia (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivololo Aurobindo Italia, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivololo Aurobindo Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure. Elevated peripheral resistance: promotes vasodilation through nitric‑oxide release, aiding blood pressure control.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially after standing. - Fatigue or tiredness: often transient. - Nasal congestion: mild nasal stuffiness. - Bradycardia: heart rate below 60 bpm. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe bradycardia: may require medical attention. - Atrioventricular block: conduction disturbances. - Bronchospasm: especially in patients with reactive airway disease. - Allergic reactions: rash, pruritus, or angioedema. - Hepatic dysfunction: elevated liver enzymes. - Marked hypotension: sudden drop in blood pressure.

Before initiating therapy, clinicians should consider several safety factors.

Monitor blood pressure: ensure adequate control without excessive drop. Assess cardiac function: evaluate heart rate and rhythm regularly. Use caution in asthma/COPD: β‑blockade may precipitate bronchospasm. Review concomitant beta‑blockers: avoid additive effects. Adjust in renal/hepatic impairment: dose may need modification. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels. - Calcium‑channel blockers (verapamil, diltiazem): may enhance bradycardic effect. - Anti‑arrhythmic agents (amiodarone): risk of severe conduction disturbances. - Insulin or sulfonylureas: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive response. - Diuretics: monitor electrolytes and blood pressure. - Other antihypertensives: cumulative blood pressure lowering. - SSRIs or SNRIs: watch for additive central nervous system effects. - Digoxin: monitor for bradycardia.